-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Thomas Hatschek, associate professor of the Department of Oncology Pathology, and his colleagues recently published an article stating that new therapies for breast cancer using antibodies linked to cytotoxic drugs are as good as previous combination therapies, but with fewer side effects
The development of antibody therapies (trastuzumab and pertuzumab) against HER2-positive breast cancer has demonstrated that if these antibodies are combined with chemotherapy (usually taxane), the possibility of treating and curing this cancer Sex will be better
A randomized phase II study of PREDIX HER2 was conducted in 9 Swedish cinics, with the purpose of investigating its efficacy (proportion of complete response after treatment) with neoadjuvant therapy) and the frequency and degree of side effects
Studies have shown that the pathological complete response effects of the two treatment groups are similar
In summary, studies have shown that the efficacy of the two treatments is the same, but patients treated with T-DM1 have fewer side effects
Neoadjuvant Trastuzumab, Pertuzumab, and Docetaxel vs Trastuzumab Emtansine in Patients With ERBB2-Positive Breast Cancer: A Phase 2 Randomized Clinical Trial.